KalVista Pharmaceuticals, Inc. (KALV) Financial Forecast
United States · Health Care · USD (Thousands) · Annual
Key financials
USD|Thousands
ROE
-121.5%
2025 (actual)
ROA
-75.46%
2025 (actual)
Gross Margin
100%
2025 (actual)
Net Margin
-
Total Assets
$250,770.00K
2025 (actual)
Net Income
-$183,444.00K
2025 (actual)
Valuation
-
Stock Price
-
Historical & projected performance
USD|Thousands
Reported figures and Equlion model projections for the next 4 years.
ROE
+120.5 pt
Company
ROA
+75.1 pt
Company
Total Assets
+0%
Company
Net Income
+99.5%
Company
Detailed data
USD|Thousands
Key metrics
Amounts in USD (thousands); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Projections are model estimates, not investment advice.
Want the full financial forecast report for KalVista Pharmaceuticals, Inc.? It covers the balance sheet, income statement, cash flow and Equlion model projections.